Labcorp Reports Strong Q3 2026 Results and Raises Full Year Guidance
Labcorp reported a 6.9% increase in Q3 2026 revenue to $3.81 billion and 14.5% growth in adjusted EPS, prompting an increase in full-year guidance and the approval of a new melanoma companion diagnostic.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed